scispace - formally typeset
W

Wouter Hoefsloot

Researcher at Radboud University Nijmegen

Publications -  77
Citations -  2497

Wouter Hoefsloot is an academic researcher from Radboud University Nijmegen. The author has contributed to research in topics: Nontuberculous mycobacteria & Mycobacterium abscessus. The author has an hindex of 19, co-authored 72 publications receiving 1843 citations. Previous affiliations of Wouter Hoefsloot include Radboud University Nijmegen Medical Centre.

Papers
More filters
Journal ArticleDOI

The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study

Wouter Hoefsloot, +66 more
TL;DR: A snapshot of NTM species distribution demonstrates that the species distribution among NTM isolates from pulmonary specimens in the year 2008 differed by continent and differed by country within these continents.
Journal ArticleDOI

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands

TL;DR: Treatment outcome for pulmonary NTM disease was suboptimal but differed by species: overall, improvement was seen in 67% of treated patients, but in only 50% of those with pulmonary M avium disease.
Journal ArticleDOI

Systematic review of quantitative clinical gait analysis in patients with dementia.

TL;DR: The literature suggests that quantitative gait analysis can be sufficiently reliable and responsive to measure decline in walking velocity between subjects with and without dementia.
Journal ArticleDOI

Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report

Sergey Borisov, +90 more
TL;DR: This global project (658 patients from 26 countries) demonstrates aDSM is feasible and serious adverse events of recommended drugs are reasonably low (overall 57 out of 504, 11.3%), but implementation needs scaling up to support patient-centred care.
Journal ArticleDOI

High mortality in patients with Mycobacterium avium complex lung disease: a systematic review

TL;DR: Despite high heterogeneity, most studies in patients with MAC pulmonary disease document a five-year all-cause mortality exceeding 25%, indicating poor prognosis, and emphasise the need for more effective management and additional prospective mortality data collection.